share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/05 05:33

Moomoo AI 已提取核心信息

Cardio Diagnostics has received a second extension from Nasdaq until June 2, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share. This follows the company's initial 180-day compliance period that began on June 3, 2024, which expired without achieving compliance.The extension was granted based on the company meeting all Nasdaq Capital Market initial listing requirements except the minimum bid price requirement. To maintain listing, Cardio Diagnostics must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is considering various options, including a potential reverse stock split.If compliance is not achieved by June 2, 2025, the company faces potential delisting, though it would have the right to appeal before the Nasdaq Hearings Panel. Currently, this notice has no immediate impact on the trading status of the company's common stock.
Cardio Diagnostics has received a second extension from Nasdaq until June 2, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share. This follows the company's initial 180-day compliance period that began on June 3, 2024, which expired without achieving compliance.The extension was granted based on the company meeting all Nasdaq Capital Market initial listing requirements except the minimum bid price requirement. To maintain listing, Cardio Diagnostics must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is considering various options, including a potential reverse stock split.If compliance is not achieved by June 2, 2025, the company faces potential delisting, though it would have the right to appeal before the Nasdaq Hearings Panel. Currently, this notice has no immediate impact on the trading status of the company's common stock.
Cardio Diagnostics已经从纳斯达克获得了第二次延期,直到2025年6月2日,以恢复对每股最低买盘价格要求1.00美元的合规性。这是继公司在2024年6月3日开始的最初180天合规期之后,该合规期已到期但未能达成合规。此次延期是基于公司满足了所有纳斯达克资本市场初始上市要求,除了最低买盘价格要求。为了维持上市,Cardio Diagnostics必须在新截止日期之前实现至少10个连续交易日的收盘买盘价格不低于1.00美元。该公司正在考虑多种期权,包括潜在的反向股票拆分。如果到2025年6月2日仍未达成合规,公司将面临被退市的可能性,尽管它有权在纳斯达克听证委员会面前提出上诉。目前,此通知对公司普通股的交易状态没有立即影响。
Cardio Diagnostics已经从纳斯达克获得了第二次延期,直到2025年6月2日,以恢复对每股最低买盘价格要求1.00美元的合规性。这是继公司在2024年6月3日开始的最初180天合规期之后,该合规期已到期但未能达成合规。此次延期是基于公司满足了所有纳斯达克资本市场初始上市要求,除了最低买盘价格要求。为了维持上市,Cardio Diagnostics必须在新截止日期之前实现至少10个连续交易日的收盘买盘价格不低于1.00美元。该公司正在考虑多种期权,包括潜在的反向股票拆分。如果到2025年6月2日仍未达成合规,公司将面临被退市的可能性,尽管它有权在纳斯达克听证委员会面前提出上诉。目前,此通知对公司普通股的交易状态没有立即影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息